Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population

TÜREDİ, SÜLEYMAN; Cinar, Orhan; Yavuz, Izzet; MENTEŞE, AHMET; GÜNDÜZ, ABDÜLKADİR; KARAHAN, SÜLEYMAN; TOPBAŞ, MURAT; Cevik, Erdem; Yildirim, Ali; Uzun, Ahmet; Kaldirim, Umit

Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population

Atıf İçin Kopyala

TÜREDİ S., Cinar O., Yavuz I., MENTEŞE A., GÜNDÜZ A., KARAHAN S. C., ...Daha Fazla

JOURNAL OF NEPHROLOGY, cilt.23, sa.3, ss.335-340, 2010 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 23 Sayı: 3
Basım Tarihi: 2010
Dergi Adı: JOURNAL OF NEPHROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.335-340
Anahtar Kelimeler: End stage renal disease, Ischemia-modified albumin, Hemodialysis, Renal failure, HEMODIALYSIS-PATIENTS, MYOCARDIAL-ISCHEMIA, PULMONARY-EMBOLISM, DIALYSIS MEMBRANE, MARKER, DIAGNOSIS
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Introduction: Conventional biomarkers suffer from the drawback of being elevated in chronic renal failure even in the absence of myocardial ischemia. Ischemia-modified albumin (IMA) is a new biomarker proposed for the diagnosis of myocardial ischemia. This study was performed with the primary aim of determining IMA levels in patients with end stage renal disease (ESRD). The secondary aim of the study was to determine the impact of hemodialysis (HD), HD speed, and hemoglobin (Hb) levels on IMA levels.